Skip to main content

Research Repository

Advanced Search

Pharmaceutical co-crystals – are we there yet?

Blagden, N.; Coles, S.J.; Berry, D.J.

Pharmaceutical co-crystals – are we there yet? Thumbnail


Authors

N. Blagden

S.J. Coles

D.J. Berry



Abstract

In the pharmaceutical arena it is agreed that co-crystals form a vital part of the solid-state toolbox, allowing the progression of novel compounds through the development pathway to patients and improving properties in older medicines. Sadly though, few co-crystals have made it to the market in the form of a new licensed product. This displays a disconnect between research effort and end product. For some time now it has been possible to determine the formation of co-crystals, by a variety of screening and analytical means; although it is recognised that there will always be phases that sit in the ‘greyer’ area of the salt-co-crystal continuum. It is also possible, with limitations, to predict the formation of co-crystals in silico via energetic and structural considerations. So what are the major hurdles and missing links, and what are the key structural properties we need to study to improve the success rate? This highlight hopes to address these.

Citation

Blagden, N., Coles, S., & Berry, D. (2014). Pharmaceutical co-crystals – are we there yet?. CrystEngComm, 16(26), 5753-5761. https://doi.org/10.1039/c4ce00127c

Journal Article Type Article
Publication Date Jul 14, 2014
Deposit Date Jun 16, 2014
Publicly Available Date Mar 29, 2024
Journal CrystEngComm
Publisher Royal Society of Chemistry
Peer Reviewed Peer Reviewed
Volume 16
Issue 26
Pages 5753-5761
DOI https://doi.org/10.1039/c4ce00127c

Files




You might also like



Downloadable Citations